EyePoint Pharmaceuticals, Inc.
EYPT
$5.55
-$0.12-2.12%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 10.11% | 11.05% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 10.11% | 11.05% | |||
| Cost of Revenue | -333.66% | 484.97% | |||
| Gross Profit | 526.21% | -520.71% | |||
| SG&A Expenses | -2.54% | 4.81% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 31.33% | -1.71% | |||
| Operating Income | -38.14% | 5.20% | |||
| Income Before Tax | -40.69% | 4.75% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -41.00% | 4.75% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -41.00% | 4.75% | |||
| EBIT | -38.14% | 5.20% | |||
| EBITDA | -38.44% | 5.39% | |||
| EPS Basic | -18.94% | 6.94% | |||
| Normalized Basic EPS | -18.66% | 6.93% | |||
| EPS Diluted | -18.94% | 6.94% | |||
| Normalized Diluted EPS | -18.66% | 6.93% | |||
| Average Basic Shares Outstanding | 18.56% | 2.34% | |||
| Average Diluted Shares Outstanding | 18.56% | 2.34% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||